Gao Lu-Hua, Nie Qing-He, Zhao Xi-Tai
Center of Infectious Diseases, Second Affiliated Hospital, Air-Force Military Medical University, Xi'an 710038, People's Republic of China.
Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910. eCollection 2021.
Hepatitis C is a major health problem worldwide, frequently resulting in cirrhosis and increasing the risk of hepatocellular carcinoma significantly. In recent years, the advent of direct-acting antivirals (DAAs) has dramatically improved the therapeutic outcomes in hepatitis C patients. In the last two years, several new DAA combinations have been approved for the treatment of the hepatitis C virus (HCV) infection, including elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir. The newly approved DAA regimens may be prescribed with other drugs simultaneously, increasing the potential of pharmacokinetic interactions. Therefore, the knowledge and management of drug-drug interactions (DDIs) with DAAs should be considered a key issue in HCV therapy. This review summarizes researches of DDIs focusing on newly approved DAAs (elbasvir, grazoprevir, velpatasvir, voxilaprevir, glecaprevir, pibrentasvir) for patients undergoing HCV treatment to provide clinical consideration for comedication. With respect to DDIs, newly approved DAA regimens, including elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir, are safely applicable.
丙型肝炎是全球主要的健康问题，常导致肝硬化，并显著增加肝细胞癌的风险。近年来，直接抗病毒药物（DAAs）的出现显著改善了丙型肝炎患者的治疗效果。在过去两年中，几种新的DAA组合已被批准用于治疗丙型肝炎病毒（HCV）感染，包括艾尔巴韦/格拉瑞韦、索磷布韦/维帕他韦、索磷布韦/维帕他韦/伏西瑞韦和格卡瑞韦/哌仑他韦。新批准的DAA治疗方案可能会与其他药物同时开具，增加了药代动力学相互作用的可能性。因此，了解和管理与DAAs的药物相互作用（DDIs）应被视为丙型肝炎治疗中的关键问题。本综述总结了针对接受丙型肝炎治疗的患者，聚焦于新批准的DAAs（艾尔巴韦、格拉瑞韦、维帕他韦、伏西瑞韦、格卡瑞韦、哌仑他韦）的DDIs研究，以为联合用药提供临床参考。关于DDIs，新批准的DAA治疗方案，包括艾尔巴韦/格拉瑞韦、索磷布韦/维帕他韦、索磷布韦/维帕他韦/伏西瑞韦和格卡瑞韦/哌仑他韦，均可安全应用。
